Tag Archive | "h"

Tags: , ,

STI +0.7%, Retracing Early Fall; 2600 Resistance

Posted on 18 August 2009 by Alex

singapore stock market ,singapore stock market news 

Singapore stocks rebound after opening tad lower on Wall Street’s losses, as buyers re-enter after yesterday’s steep fall. STI +0.7% at 2,564.49 vs early low of 2,541.35 (off 0.2%), while market breadth flat. Resistance for STI tipped at 2,600, while any further pullback may find support at 2,500. “If you plan to buy, it’s best to do it little by little and not be greedy because you never know if a correction is just around the corner, especially after what happened in the market yesterday,” says local house trader. Overall market volume light, with lower lines among most active.

Comments (3)

Tags: , , , , ,

singapore stock market news

Posted on 12 August 2009 by Alex

Singapore Q2 GDP jumps revised 20.7 percent

SINGAPORE - Singapore revised slightly higher its economic growth in the second quarter, but warned U.S. consumption must pick up to sustain the recovery.

Gross domestic product grew an annualized, seasonally adjusted 20.7 percent in second quarter, the Trade and Industry Ministry said in a statement Tuesday. The ministry last month initially reported a 20.4 percent expansion.

Manufacturing surged 49.5 percent, construction jumped 32.7 percent, and financial services rose 22.8 percent from the previous quarter, the ministry said.

“This improvement was largely driven by the spike in output from the volatile biomedical manufacturing cluster and inventory re-stocking,” the ministry said. “Financial services was boosted by sentiment-sensitive segments such as stock market activities.”

“It is uncertain if these can be sustained into the second half.”

Before the April to June period, the economy contracted the previous four quarters as the global recession undermined demand for Singapore’s exports. The government expects the economy to fall up to 6 percent this year.

GDP shrank 3.5 percent in the second quarter from a year earlier, better than the previous estimate of a 3.7 percent contraction, the ministry said.

Non-oil exports, which account for about 60 percent of GDP, rose a seasonally adjusted 7.6 percent in the second quarter from the first quarter, while falling 14 percent from a year earlier, the ministry said. The government expects non-oil exports to contract up to 12 percent this year.

An economic recovery in the second half and next year will likely be muted unless U.S. consumer demand grows more than expected, Ravi Menon, deputy trade ministry, said at a news conference.

“The subdued and weak recovery that we see taking place in the second half of this year is likely to continue to next year,” he said. “That’s not a bad outcome if we continue to avoid financial slippages and double dip recession scenarios.”

Comments (0)

Tags: , , , ,

australia stock market

Posted on 11 August 2009 by Alex

The stock of this oil and gas exploration company (ASX: KAR) has recently peaked at $12.10 on last July 24. It’s an historical high price, far above the previous highs posted during the previous years. Oppositely to many other energy-related stocks, KAR soared to unprecedented high levels after it hit a low in last October at $1.645. It rose therefore by 635% in 8 months and a half (between points A and B on the chart).
 

 

A new bullish wave?

 

The stock really took off when the market bounced at mid-March this year. The bullish trend has been split in a succession of three sharp upward waves followed by corrections. These bullish waves are plotted in blue rectangles on the chart. That’s why the uptrend has been so solid and durable: the price action regularly posted higher highs and higher lows which built a clear stepped incline.

Since the price action posted this high at $12.10, it has already corrected by 12.4%. The current price is $10.6. Is it a typical short-term correction that precedes another bullish wave or is it more than that?

First we have plot a trading system based on the Chande Momentum Oscillator, which is particularly accurate here. You can see that the “SELL” trading signals were triggered with efficient market timing, on top of each of the three bullish waves. The Relative Momentum Index (RMI), which was moving within its overbought area since last June, has just reached its 70-line. A cross below this line would confirm that the correction is not over yet.

The immediate target is the level of $9.3, which is 12.3% lower than the current level. The medium-term bullish trend generated in March would be cancelled if price action falls below. It would mean than the intermediary support level created by the previous high is cleared. In this case, the new objective would the level of $8, another high that may become a new low.

Comments (0)

Tags: , , , , , , , , , , , , , , , , , , , ,

singapore stock market news

Posted on 30 July 2009 by Alex

BIOSENSORS, csfb maintain OUTPERFORM with target price $0.8($0.9) EPS for
FY09/10 revised to UNCHANGED and raised by 48%
BIOSENSORS, ocbc maintain BUY with target price $0.74

CAMBRIDGE, dbs downgrade to HOLD with target price $0.41($0.44) EPS for
FY09/10 lowered by 4% and 9%
CAMBRIDGE, rbs remains a HOLD with target price $0.40(from $0.23)

CAPITALAND, csfb maintain OUTPERFORM with target price $4.21

CHARTERED SEMI, jpm maintain NEUTRAL with target price $2.10

CHINA XLX, cimb downgrade to UNDERPERFORM from NEUTRAL with target price
$0.34
CHINA XLX, dbs maintain FULLY VALUED with target price $0.44($0.37)

DBS, rbs maintain downgrade to HOLD from BUY with target price $13.50($14)

GENTING SP, dbs reinitial coverage BUY with target price $0.98

MAPLETREE LOGISTICS TRUST, ubs maintain BUY with target price $0.87($0.67)

OCBC, rbs downgrade to HOLD from BUY with target price $8

RAFFLES MEDICAL, cimb maintain OUTPERFORM with target price $1.19($1.04)
RAFFLES MEDICAL, csfb maintain OUTPERFORM with target price $1.65
RAFFLES MEDICAL, db maintain HOLD with target price $0.68
RAFFLES MEDICAL, dbs maintain HOLD with target price $1.06($0.91)
RAFFLES MEDICAL, kim eng maintain BUY with target price $1.38
RAFFLES MEDICAL, nom maintain BUY with target price $1.30

SATS, cimb maintain UNDERPERFORM with target price $1.37

SIA, cl maintain UNDERPERFORM with target price $12.02 EPS for FY09/10
lowered by 46.5% and 53.2%
SIA, ssb maintain SELL with target price $13.35
SIA, ubs downgrade to SELL from NEUTRAL with target price $13

SIA ENGINEERING, cimb downgrade to NEUTRAL from OUTPERFORM with target
price $2.97
SIA ENGINEERING, dbs downgrade to HOLD from BUY with target price $3($3.20)
EPS for FY 10/11 lowered by 7% and 5.6%
SIA ENGINEERING, jpm maintain NEUTRAL with target price $3.20($3)
SIA ENGINEERING, nom maintain BUY with target price $3.28($2.18) EPS for
FY10-11 raised by 17.9% and 28.5%
SIA ENGINEERING, ocbc maintain HOLD with target price $2.95

SINGTEL, db maintain HOLD with target price $3.24

SMRT, uob maintain BUY with target price $2

UOB, rbs maintain BUY with target price $18.50($17)

WILMAR, gs maintain BUY with target price $6.50
WILMAR, uob maintain BUY with target price $6.50($4.80)

Comments (0)

Tags: , , , ,

singapore stock market news

Posted on 30 July 2009 by Alex

BIOSENSORS, csfb maintain OUTPERFORM with target price $0.8($0.9) EPS for
FY09/10 revised to UNCHANGED and raised by 48%
-  Biosensors reported its 1Q10 (quarter-ended June) results after market
close on 27 July . the first profitable quarter in its history. Revenue was
in line with the company.s guidance.
-  Profit from its China JV (JWMS) remained strong with 100% growth YoY,
12% growth QoQ . the JV contributed 74% of Biosensors.s 1Q10 EPS. The
company expects to receive Chinese SFDA approval for its BioMatrix in next
9-15 months.
-  With US$50 mn cash as of June and its positive free cash flow, the
company believes it can pay the US$48 mn convertible bond, which is due in
November 2009. We, however, believe near-term fund raising may be
inevitable.
-  With encouraging 1Q10 results, we raise our FY10E EPS by 48%, but reduce
FY11E EPS by 28% . we expect competition to intensify due to the planned
2010 launch of NEVO and Boston Scientific.s drug-eluting stent (DES) with
biodegradable polymer . but Biosensors. likelihood of being acquired has
increased. Maintain OUTPERFORM with but reduce our target price from S$0.90
to S$0.80.

BIOSENSORS, ocbc maintain BUY with target price $0.74
-Net profit position, purely through core business. Biosensors
International Group (Biosensors) posted results that beat our expectations.
The group posted 1Q10 revenue of US$23.8m (+6% QoQ, -66% YoY) and net
profit of US$4.2m (about 10x QoQ growth). Stripping out the one-time US$41m
licensing fee in 1Q09, gross profit would have grown about 70% YoY. This
quarter is especially pivotal as the group’s performance was primarily
driven by its core business, not through exceptional items.
-Importance of market share acquisition. We iterate that Biosensors has
embarked on the right strategy to sustain its market share acquisition
track by growing its topline. While profitability remains a key component
of every company’s financials, growing sales on a QoQ basis implies growing
market acceptance and product entrenchment within the medical community.
This is important for any new product launch but especially for a growing
medical device company like Biosensors. Sales for its key BioMatrix product
sustained its growth trajectory of 8% QoQ and 59% YoY. Its other product
divisions also turned in better-than-expected sales with improved margins.
-JW Medical System outperforms. Biosensor’s 50%-owned JWMS outperformed
expectations this quarter, contributing US$3.1m (+100% YoY, +11% QoQ) to
Biosensors. Management was upbeat about its sales and expects that
sustained performance from this unit would aid it in its eventual
penetration into the Chinese market with its BioMatrix Drug Eluting Stent
(DES) that is pending approval in China (12-15 months later). Management
also dispelled market rumours that it would be divesting JWMS. It
highlighted that JWMS’ CEO is a Biosensors employee and that strong link is
critical in the long run to manage any technology transfer in the Chinese
market.
-Competitors help create a wake. J&J (with its Nevo Stent) and Boston
Scientific (with its acquisition of Labcoat in Jan 09) indicated that their
future DES developments would embrace biodegradable polymer technology.
Biosensors can effectively utilise the technology marketing wake created by
these two large companies to jump start sales again. Biosensors will be
presenting its 2-year follow-up LEADERS trial results in Sep 09. We are
expecting positive newsflow.
-Maintain BUY. We have retained our estimates and prefer to see
sustainability of JWMS performance and a more predictable pattern in
licensee royalties prior to refining forecasts. We are maintaining our
medtech discounted model with a fair value of S$0.74.

CAMBRIDGE, dbs downgrade to HOLD with target price $0.41($0.44) EPS for
FY09/10 lowered by 4% and 9%
-Results in line. Cambridge Industrial Trust (CREIT) 2Q09 results were in
line with expectations. Results were underpinned by a portfolio mainly
secured on sale and leaseback leases. Distributable income came in 14%
lower at S$10.7m (DPU of 1.345 Scts), largely a result of management fees
paid in cash and higher borrowing costs.
-Private placement- to National Australia Bank/ Oxley. In a recent
announcement, Cambridge REIT announced a private placement exercise @
S$0.39 per unit to National Australia Bank & Oxley to raise cS$28m of
proceeds. Total shares to be issued are estimated to be c.10% of share
base.
-Proceeds for asset enhancement purposes. Proceeds from the placement will
be utilized to embark on asset enhancement initiatives (50-70%) and general
working purposes (50-30%). While we understand that several of their assets
have yet to fully utilize their plot ratios, raising equity at c. 12 -13%
yield does present a relatively high cost of capital hurdle to overcome in
order to make any investments accretive. In addition, Cambridge REIT may
have to seek respective tenants’ approval before embarking on any
meaningful enhancement works, which could mean that the potential impact on
earnings is likely to be delayed.
-Downgrade to HOLD. DPU is expected to be diluted by c7- 9% in FY09-10F to
c. 4.8 ­ 4.7 Scts. Our DCF based TP will be reduced to S$0.41, which is
close to its closing price. As such, we downgrade to HOLD. Cambridge REIT
currently offers a FY09-10F yield of 12%.

CAMBRIDGE, rbs remains a HOLD with target price $0.40(from $0.23)
- We raise CREIT’s earnings after the 2Q09 results on a
stronger-than-expected occupancy rate and lower interest costs. But, a weak
industrial property market and a potential second round of equity raising
dampens our outlook. We estimate the impending placement will dilute DPS by
8%. Hold, with a new TP of S$0.40.
- Earnings raised on strong occupancy and lower interest costs in 2Q09. We
raise our distributable income forecasts for CREIT by 30% to S$40.3m in
FY09 and 31% to S$40.5m in FY10. It achieved a strong occupancy rate of
99.5% in 2Q09, vs our previous assumption of 90% in FY09-10. We assume a
vacancy rate of 1% in FY09 and 2% in FY10 to reflect CREIT’s portfolio
resilience. We lower our cash interest by S$5.1m-5.9m in FY09- 10F, due to
the reclassification of the S$18m interest swap as a non-cash expense.
- Planned private placement will dilute FY09-10F DPU by 8%. CREIT has
announced a private placement to raise S$28m at S$0.392/unit, a discount of
5.5% to its last traded price. A portion of the placement units can be
offered to NAB and Oxley, which are managers of the placement, at
S$0.399/unit. Most of the proceeds (50- 70%) are to be used for capex and
the rest for working capital. Up to 79.6m units, or 10% of CREIT’s current
units outstanding, can be issued, but we estimate placement units of 71.4m.
This would dilute DPU by 8.3% in FY09F to 4.64 cents and by 8.1% in FY10F
to 4.67 cents.
- We see the possibility of a second round of equity raising. CREIT
devalued its portfolio by 9% hoh to S$880m in June, bringing its LTV to
45%. We estimate the portfolio value would need to drop another 10% before
its LTV covenant of 50% is breached. Management believes that further
devaluation is unlikely and says that it may undertake a dividend
reinvestment scheme (DRS) and asset divestments to mitigate the risk of
falling values. In our view, most shareholders will not opt for DRS and
selling properties could be difficult in the current climate. Thus, our
valuation model assumes a fresh equity raising of S$44m (vs S$90m
previously) to cater to a potential 15% fall in property value.
- Hold, with a higher target price of S$0.40. We lift our DCF-based target
price to S$0.40 (from S$0.23) due to the earnings upgrade and a reduction
in our equity-raising assumption. We also factor in potential dilution from
the private placement. We find CREIT’s yield compelling, at 12%+, in FY09F
and FY10F.

CAPITALAND, csfb maintain OUTPERFORM with target price $4.21
-  Australand Monday announced 1H09 net loss of A$268.8 mn, after writing
down A$235 mn at its investment properties and A$93 mn development and JV
inventory impairments.
-  Simultaneously, Australand announced a 7-for-10 nonrenounceable rights
issue of stapled securities in Australand to raise a fully underwritten
A$475 mn. This is at an issue price of A$0.40 (S$0.47) per new stapled
security, representing a 20% discount to the closing price on 24 July 2009.
-  Capitaland has cash hoard of S$5.5 bn and net gearing of 32%. This is
more than enough for CAPL to subscribe to its entitlement at ALZ.
-  With most of its listed entities/REITs results out last week and Monday,
we expect CAPL’s 2Q09 and 1H09 results to be a net loss as most of its
listed entities recorded write-downs. We believe investors should look
beyond the accounting technicalities and recommend accumulating on dips.
Maintain OUTPERFORM on a target price of S$4.21, based on parity on RNAV.

CHARTERED SEMI, jpm maintain NEUTRAL with target price $2.10
- 2Q09 report in line, 8″ Fab remains far behind average utilization CHRT
reports 2Q09 sales of $349mn and net loss of $39mn, which is inline with
company guidance, but sales is about 4.4% below our estimate and net loss
is about 22% better than our estimate. We believe the discrepancy may come
from the lower-than-expected 8″ Fab utilization and a slightly better ASP
from the product mix. If we assume CHRT 12″ Fab to have been fully
utilized, then the 8″ Fab utilization was at around 50% versus the average
70% utilization rate in 2Q09.
- Guides to strong growth in 3Q09 and continued growth in 4Q09 Chartered
guided a positive sales growth of 9-13% for 3Q09, higher than our prior
growth estimate of 5-9%. We believe the growth momentum is coming from the
65nm in communication segment and the mature technologies in PC segment.
The company’s management also indicates likely profitable 4Q09 scenario
exceeding 75% utilization, and the growth drivers may come from both the
advanced and matured technologies.
- 2009 CapEx increase to meet rising 65nm demand from communication space,
no ROE targets in sight CHRT announces to increase 2009 CapEx from $375mn
to $500mn, aiming to add Fab-7 12″ capacity from about 25K per month to
about 31K by the end of 1Q10. We believe the company is facing strong 65nm
demand in mobile phone and broader communication space. CHRT is targeting a
cash balance of US$700 million by end-2009, higher than our current
estimate of ~US$610 million. The company clearly has neither any specific
Return on Capital targets nor a view on long term industry growth ­ two
important variables that we believe the company should use in order to
decide capital spending plans. In this regard, foundry sector continues to
look somewhat unattractive relative to back-end space.
- Maintain Neutral but raise our Jun-10 PT to US$14/S$2.1 We maintain our
Neutral rating on Chartered Semiconductor and roll over our price target
timeframe to Jun-10 from Dec-09. Our revised price target is S$2.1 (CSM SP)
/ US$14 (CHRT US), which is based on 0.75x TTM (Jun-10) book, still at a
discount to book given the negative ROE expected in 2010E and 2011E and
liquidity risk.

CHINA XLX, cimb downgrade to UNDERPERFORM from NEUTRAL with target price
$0.34
-CXLX announced this morning that it is contemplating a dual listing of its
shares on the main board of the Hong Kong Stock Exchange, so that it can
have ready access to different equity markets in the Asia Pacific when
opportunities arise.
-CXLX has appointed professional parties to commence preparatory work for
the proposed listing. Further announcements will be made once an
application has been filed with the Hong Kong Stock Exchange. An EGM will
be held at a later date to seek shareholders’ approval.
-This proposed dual listing might not work as well as perceived. We believe
CXLX’s discount to its Hong Kong peers might not narrow following a Hong
Kong listing, given its limited urea export exposure compared with China
BlueChemical (3983 HK) and its less diversified portfolio compared with
Sinofert Holdings (0297 HK).
-Liquidity could be affected. Additionally, it is possible that there will
not be any new shares issued for the dual listing, i.e. CXLX will have to
“take out” existing shares on the SGX and “transfer” them to Hong Kong.
That would undermine its trading liquidity. We also believe that the two
markets will not necessarily expose CXLX to a wider range of private and
institutional investors.
-Situation remains fluid. The listing may or may not occur, pending the
results of the preparatory work and market conditions.
-But overall picture still bleak. CXLX’s urea ASP stays low, as
overcapacity in the Chinese market limits its ability to raise sales volume
and ASPs. Management is also uncertain when the oversupply will end. In
fact, it has guided that urea prices could remain weak for a period of
time. Chinese urea exports remain uncompetitive at the current export tax
rate. Additionally, CXLX’s tax holiday has expired and the company will
attract a 17.5% tax rate in FY09-11.

CHINA XLX, dbs maintain FULLY VALUED with target price $0.44($0.37)
-Seeking dual-listing in HK. China XLX announced this morning that the
Group is proposing a dual-listing in HK. This is still at very preliminary
stage with no details . The proposal is subject to the approval of Hong
Kong Stock Exchange and the approval of the Shareholders.
-Valuation gap should be narrowed in the event of successful dual-listing.
Historically, CXLX has been trading at a discount of 25%-35% to its HK
peers. The dual-listing should positively impact CXLX’s valuation in
Singapore. We believe the valuation gap between CXLX and its closet peer in
HK, China Bluechem would be narrowed. However, a marginal discount should
remain, in view of China Bluchem’s much larger market capitalisation and
SOE premium.
-Maintain FV, TP raised to S$0.44. Share price has run ahead on speculation
of the dual-listing in HK, where discussion is still preliminary at this
point. We roll over our valuation to blended FY09/10 earnings and TP is
raised to S$0.44, still pegged to 9x PE. In the event of a successful
dual-listing, we believe the fair value should be adjusted to S$0.53 at 11x
PE, which is a 10% discount to its closet peer, China Bluechem. We advise
investors to sell into strength.
-Fundamentals remain weak. The dual-listing is deemed to be a positive
development for CXLX, in terms of valuation. However, the outlook of the
company remains gloomy. The issue of urea oversupply is unlikely to be
resolved this year and fluctuations in coal cost could further dampen the
earnings of the company.

DBS, rbs maintain downgrade to HOLD from BUY with target price $13.50($14)
-We downgrade DBS to Hold following its 49.6% ytd price appreciation. The
valuation is attractive, but we struggle to identify a clear catalyst to
unlock this value. We cut our FY09F to FY11F earnings by an average of 4.4%
to reflect a lower loan spread assumption and set a new S$13.50 target
price.
-Key investment considerations. Following DBS?ytd outperformance (up 49.6%
vs 46.3% for OCBC and 25.7% for UOB) we downgrade to Hold. From here on the
following key investment considerations should dominate, in our view 1)
DBS?key attraction remains its valuation (1.5x FY10F P/TCE, vs 1.7x for
OCBC and 2.0x for UOB). With the good news on loan repricing and asset
quality fully discounted, we see no immediate catalyst to unlock further
value. 2) DBS remains at the mercy of low Sibor. Its NIM improvement has
been lagging those of peers (1Q09 NIM was actually down 5bp at 199bp vs
FY08 at 204bp, while its two peers showed improvements). With Sibor
seemingly lower for longer, and loan yields flattening out, DBS?NIM is
likely to continue to lag those of its peers. 3) Following its capital
raising earlier this year, DBS earns the lowest RoTCE of its peer group
(11.4% FY09F). With NIM improvement flattening out, loan growth subdued and
bad debt charges remaining at an elevated level, we don? expect DBS to
close the RoTCE gap vs its peers and we forecast FY11 RoTCE at 12.6%, vs
14.9% for its peer group.
-2Q09 results should be in line with strong 1Q09 ?problems start after
that. DBS reports 2Q09 results on 7 August. We expect results to be in line
with the strong 1Q09, and net profit to hold steady qoq at S$434m (before
any potential gains from the sale of its 2.7% stake in HDFC), although this
would represent a 33.5% yoy decline. Key issues that the market is likely
to focus on include NIMs (we forecast a 1bp qoq improvement to 200bp), bad
debt charges (we forecast 130bp versus 127bp in 1Q09), especially for the
Hong Kong operation, and the dividend (we expect S$0.14, flat qoq).
-Downgrade to Hold with S$13.50 target price. We downgrade to Hold
following the share? relative outperformance ytd. We marginally cut our
FY09F to FY11F estimates to reflect a 5bp cut in our loan spread
assumptions, as we now believe loan spreads will flatten out.

Comments (0)

Tags: , , , , ,

us stock market

Posted on 13 February 2009 by Alex

If I recall correctly from the Four Corners show on Australian ABC TV this week Gerry Harvey admitted to losing about $1.5 billion in wealth in the last year or so – but still has a cool billion left. This was a billion he never had within his sights or reckoning years ago so he is still laughing.

My apologies to our international readers to talk of a local identity – but what I am about to discuss is relevant for all investors all over the world. Basic principles transcend country boundaries.

Gerry Harvey lost his $1.5 billion primarily by buying his own stock – that is in his listed company Harvey Norman – HVN. To his credit Gerry Harvey spoke openly about his foolhardiness to buy more as his stock share price continued to slide.

In global investing language this is called dollar cost averaging but for some existing dominant shareholders in any company there can be other motivations for buying more of your own stock. This can be blind belief in one’s self, it can be a belief that you can prop up your company’s share price alone or with a small group of friends or it can be sheer desperation to save what is left in your existing shareholding especially if it is leveraged. I am not saying that these motivations exist in every case but they are common reasons why investors pour more money into an asset declining in value.

Gerry Harvey lost $1.5B. Theoretically his wealth may have been up at $2.5billion when his share price may have been around $7 – and now it is around $2. I have not bothered to do the maths because I almost cynical about the top share price or anything around those level. As that does not represent the value of a company but rather it is a theoretical value some foolhardy investor has unwittingly (perhaps) put on that company’s share price.

I also remember the Fundie, I mentioned only a few editions ago, was telling me how he thought Macquarie’s share price would hold up because its key management had deep pockets. Well MQG is down over 30% since that conversation. You mean Macquarie executives also believe in dollar cost averaging?

Basic Principle: Don’t follow a falling share price – for whatever reason – no matter how much cash you have – as the market is going to deal with that stock in a way only markets can – and for all you know that could be in a very severe manner.

Comments (0)

Tags: , , , , , , ,

australia stock market

Posted on 04 February 2009 by Alex

Why a Small Deficit is Just The Tip of a Big Deficit Iceberg

You already know what the big news of today is going to be so we’ll skip that and comment on it tomorrow.

Of course the other big news is rumoured to be that two million households will get ceiling insulation funded by the government. It is almost too crazy to think about. We don’t know for a fact whether it’s true, but that seems to be the gossip. Your editor’s brain just does not compute why the federal government is diversifying into the household insulation business.

Maybe there is good money in it. We don’t know. But what we do know is that whether you like it or not, you will be buying someone, somewhere, some ceiling insulation. Perhaps the government could pass on your name to those that take the government up on the offer so they can send you a ‘thank you’ card.

But we won’t write about that either. Wayne Swan is due to release details of the latest ’stimulus package’ at 12.30 (AEDT) today. Nothing we write will be able to compete with the entertainment of seeing housing insulation touted as the saviour of the economy.

Instead we’ll take a bash at the “Budget’s $115bn black hole” and the impending “small” deficit that the government is about to plunge us into.

If you’ve been reading Money Morning or the Daily Reckoning over the last few years you’ll know that your editor has argued against the build-up of government profits - or as they and the mainstream press like to term it, government surpluses.

Our argument has always been that the government should not be a for-profit entity. That if it is drawing in surplus revenue it should stop and give it back.

By the same token the government is now signaling that it is about to go into deficit. And unsurprisingly public funded organizations such as the IMF and World Bank are suggesting that going into deficit is a good move as it will help to power the economy out of recession.

Again unsurprisingly, most economists, business groups and welfare groups are also urging the government move into deficit.

But if you thought the ceiling insulation initiative was madness then you’ll love some of the comments about prior surpluses and the soon to be realized deficit.

Apparently, according to most of the talking heads we’ve seen on television and heard on the radio, it is good that the government had built up a $20 billion-plus surplus because otherwise the economy would be in worse shape and the deficit would be even higher.

And they say it with a straight face. It is like saying to a gambler, “It’s a good job you won all that money last year because now you’ve lost it all. Imagine if you hadn’t won, you would have been even worse off now.”

It gets even better than that. ABC radio interviewed Joshua Gans, professor of economics at the University of Melbourne, he said:
“If there’s a free lunch out there where we can reduce taxes and increase tax revenues, we should definitely take it. But I don’t know how that free lunch has appeared right now.

No we wouldn’t. The idea is that not only do you cut taxes but that you cut spending as well. It’s not rocket science, and you don’t need to be a professor to work that one out. Anyway, Professor Gans continued:
“Ronald Reagan, he tried this. He had this theory, it did not show up. They dropped taxes; all they got was a bigger deficit for a decade. I don’t see any possibility of this occurring here in Australia right here, right now. And even if did, the last thing we would necessarily want to be doing is taking more in total dollar taxes out of the economy and making a bigger government.”

OK, he’s getting the idea, don’t raise taxes and keep the government small. But then unfortunately the Prof goes askew again:
“It’s probably time to bring forward the big ticket infrastructure expenditure items that the Governments might have put off for some years because the time wasn’t right.”

In other words, government spending! But it’s not just Professor Gans who is all over the shop on his economic theory. In the same story the ABC interviewed another boffin, Professor Raja Junankar from the University of Western Sydney.

He is also against giving taxpayers money back to taxpayers. He also thinks that government knows how to spend your money better than you do. This is what he said when asked whether broad-based tax cuts were a good idea:
“I think there’s no evidence to support that kind of view. In fact, after a moment, because the economy is in a recession or getting into a much worse recession over the next few years, next few months, that cutting taxes probably is not going to stimulate any extra activity. The only thing that’s going to stimulate more activity is if you can increase aggregate demand in economy, which means increasing spending on infrastructure, on hospitals, on schools, on roads and those kind of big expenditure patterns that we want to increase.”

Again, we’re not sure that we need to repeat again our view on throwing more money into the black hole of state funded health and education.

But this is surely what will happen. And it is why the mooted small deficit will sooner rather than later turn into a big deficit. Simply because one-off spending on these big white elephant projects will only lead to even bigger recurrent expenditure in future years.

The economists and mainstream press seem to forget that the only way to deliver a stimulus to the economy is to give more money back to taxpayers. This will lead them to either spend it, or more likely they will save it.

If they save it in a bank then it adds to the banks’ capital base which then allows them to lend money as consumer or business lending.

Paying for ceiling insulation and encouraging every to spend, spend, spend may have a short term positive impact for some businesses, but in the long run the increase in government debt will only have the effect of drawing money away from the private sector towards the public sector as the government refinances its own debt.

The bank’s have already loaned out as much as they can, rather than trying to patch things up with government guarantees and a ‘Rudd Bank’ the government should just cut taxes and let people save. This will naturally recapitalize the banks and it won’t cost the taxpayer a cent.

Instead, the deficit will continue to grow and grow, and because it has been in profit until recently, the Australian government has the ability to borrow much more relative to the size of the economy than the US and the UK.

Other Stuff on the Markets

Everything seemed to fall last night, the Dow Jones, Crude Oil, Gold and the Aussie Dollar. The Aussie may come under further pressure if the RBA cuts by more than 100 basis points today.

The market continues to build in a 100 basis point cut. In fact, according to the implied yields there are bets that the RBA could cut even further.

Business lobby groups are keeping up the pressure on government to spend your money. The Australian Chamber of Commerce and Industry wants the government to spend up to $25 billion. No doubt to prop up the businesses of its members.

Gold Coast property tycoon Jim Raptis has seen his company collapse with debts of around $1 billion. Is this the sort of over-leveraged property investment that the new property bail out would have financed?

Comments (0)

Advertise Here
Advertise Here